Robin Sitver, MBA is a seasoned strategic planning and corporate development executive focused on delivering business profitability, growth and performance through mergers, acquisitions, licensing and strategic initiatives. She has over 40 years of experience working at Johnson & Johnson (J&J) and Pfizer. She is recognized for her expertise in planning, negotiating, executing and flawlessly integrating complex cross-border transactions. At J&J, she successfully closed more than 60 transactions worth over $7B, including the $2.1B divestiture of the LifeScan diabetes company to Platinum Equity. Robin is the CEO/Founder of SitverStrategy LLC, a boutique M&A consultancy. She co-chairs the Association for Corporate Growth New Jersey Corporate Development group and is a Certified Licensing Professional (CLP). Robin holds an MBA from the Wharton School of the University of Pennsylvania and a BA in Computer Science from Brandeis University. Robin provides oversight and guidance to Tempo on business development, planning and other strategic initiatives. Robin is an investor in Tempo.